Sheppard Mullin advised Kiromic Biopharma on the deal. Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
